The growing role of real-world evidence (RWE) across research, development, and decision-making has provided new opportunities for contract research organizations (CROs) operating in this space. However, the market of CROs delivering RWE is structurally unequal. With the notable exception organizations with proprietary data assets such as IQVIA, most CROs do not own large-scale proprietary healthcare datasets. Instead, they depend on third-party data vendors.
This lack of data ownership is a defining constraint that might affect competitiveness, execution, and regulatory risks. CROs operating under this model face limitations that cannot be fully eliminated, but that can be mitigated through disciplined execution and quality of service. Understanding where mitigation is possible (and where it is not) is essential for both sponsors and CROs engaged in RWE partnerships.
Structural disadvantages in the absence of data ownership
CROs without proprietary datasets are inherently less competitive on access, cost predictability, and timelines. Data acquisition is typically a pass-through expense, subject to vendor-specific pricing, contracting timelines, and governance requirements. Unlike data-owning providers, these CROs cannot leverage economies of scale across multiple programs or amortize investments in data platforms over proprietary assets.
Data governance further constrains execution. CROs working with external data must operate within frameworks defined by data owners, which often limit transparency into upstream curation processes. Decisions regarding data refresh cycles, linkage methodologies, or retrospective corrections are frequently outside the CRO’s control. Once a dataset is contracted and delivered, opportunities for iterative refinement may be limited by governance or cost considerations.
Equally important is the issue of data familiarity. When datasets are acquired externally and used episodically, institutional knowledge of source-specific limitations is necessarily incomplete. Longitudinal understanding of changes in coding practices, data capture policies, or site participation, knowledge that develops naturally in data-owning organizations, must instead be reconstructed program by program.
These factors place non-real-world data-owning CROs at a structural disadvantage relative to vertically integrated competitors. Quality of service cannot fully offset these limitations, but it can materially influence whether they undermine confidence in the resulting evidence.
Where quality becomes decisive
In the absence of data ownership, differentiation shifts almost entirely to execution. The CRO’s value lies in its ability to manage complexity across data vendors, internal teams, and sponsors, while maintaining continuity and coherence throughout the study lifecycle.
Project management becomes a primary quality driver. In RWE studies, poor coordination manifests quickly: misaligned assumptions between protocol and data availability, delays due to unclear responsibilities, and late-stage revisions that could have been avoided. CROs that perform well in this space demonstrate proactive planning, clear escalation pathways, and disciplined control of timelines and deliverables.
Team stability is another under appreciated differentiator. High turnover among project leads, analysts, or scientific contributors erodes continuity, increases the risk of inconsistent decisions, and burdens sponsors with repeated on-boarding. CROs that invest in retaining experienced teams and minimizing mid-project handovers consistently deliver smoother execution and more predictable outcomes.
Scope discipline is equally critical. RWE projects are particularly vulnerable to incremental scope expansion driven by evolving questions, exploratory analyses, or newly identified data limitations. High-quality CROs are transparent about the implications of scope changes, articulate trade-offs clearly, and resist silent drift that compromises timelines and budgets.
Transparency as an operational asset
When data are externally sourced, transparency is not optional. It is a functional requirement. CROs that distinguish themselves in this model document assumptions, data limitations, and analytical decisions in a way that allows sponsors to understand not just what was done, but why it was done that way.
This transparency extends beyond formal documentation. It includes early communication of risks, realistic framing of what the data can and cannot support, and avoidance of overconfident conclusions. Sponsors consistently value partners who surface inconvenient truths early over those who deliver polished results late.
Competence over credentials
In non-real world data-owning CROs, competence is demonstrated less by brand positioning and more by day-to-day behavior. This includes the ability to translate research questions into feasible designs given the available data, to anticipate downstream challenges, and to integrate input from statisticians, epidemiologists, clinicians, and programmers without fragmentation.
Operational competence also shows in how CROs interact with data vendors: negotiating realistic timelines, validating data deliveries thoroughly, and maintaining alignment between contractual terms and analytical needs. These activities are rarely visible in final reports, but they often determine whether a study proceeds smoothly or becomes reactive.
The intentional development of deep, source-specific and country-specific internal capabilities is a further differentiator. In the absence of proprietary data, competence increasingly depends on sustained familiarity with particular datasets, healthcare systems, and regulatory environments. Teams that repeatedly work with the same sources or geographies accumulate practical knowledge about data generation processes, coding conventions, governance constraints, and historical changes that cannot be recovered through documentation alone. This specialization enables more credible feasibility assessments, more efficient study execution, and more defensible interpretation of results. For non-real world data-owning CROs, investing in such targeted expertise is one of the few mechanisms available to offset structural disadvantages and to deliver consistency across programs rather than episodic performance.
The sponsor’s influence on execution quality
Execution quality is not the sole responsibility of the CRO. Sponsors may play a critical role in enabling or constraining performance. Projects that prioritize speed and cost without clearly defining quality expectations create ambiguity that undermines delivery. Conversely, sponsors who articulate objectives clearly, respect governance boundaries, and engage in timely decision-making reduce friction and improve outcomes.
High-performing collaborations are characterized by shared ownership of trade-offs. When limitations are acknowledged jointly and decisions are documented transparently, externally sourced RWE becomes more predictable and more credible, regardless of its ultimate use.
Redefining value in non-owned data models
For CROs without proprietary real-world data, value cannot be anchored in access or scale. It is created through reliable execution: stable teams, disciplined project management, respect for scope and timelines, strong competence, and consistent transparency. These attributes do not eliminate structural disadvantages, but they determine whether those disadvantages are manageable or destabilizing.
From a sponsor perspective, selecting a CRO in this space requires looking beyond datasets and platforms to the less visible aspects of delivery. From a CRO perspective, sustained competitiveness depends on treating execution quality not as support, but as strategy.
Conclusion
Operating without data ownership defines both the limitations and the opportunities for most CROs delivering RWE. Structural constraints are real and cannot be wished away. However, within these constraints, differentiation is driven by how studies are executed, not by what data are owned.
In RWE, credibility and usefulness are built over the course of a project, through consistent decisions and disciplined delivery. For CROs without data assets, quality is not a slogan, it is the only durable differentiator.
